CRISPR Therapeutics AG
CRSP
$43.50
-$2.03-4.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.69M | 602.00K | 517.00K | 504.00K | 201.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.69M | 602.00K | 517.00K | 504.00K | 201.21M |
| Cost of Revenue | 82.16M | 93.31M | 132.30M | 123.14M | 115.14M |
| Gross Profit | -46.46M | -92.71M | -131.78M | -122.63M | 86.06M |
| SG&A Expenses | 18.12M | 17.42M | 19.48M | 17.95M | 16.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.28M | 110.73M | 151.78M | 141.09M | 131.62M |
| Operating Income | -64.59M | -110.13M | -151.26M | -140.59M | 69.58M |
| Income Before Tax | -36.61M | -85.07M | -125.12M | -115.87M | 89.58M |
| Income Tax Expenses | 700.00K | 876.00K | 1.29M | 724.00K | 233.00K |
| Earnings from Continuing Operations | -37.31M | -85.94M | -126.41M | -116.59M | 89.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.31M | -85.94M | -126.41M | -116.59M | 89.35M |
| EBIT | -64.59M | -110.13M | -151.26M | -140.59M | 69.58M |
| EBITDA | -59.75M | -105.39M | -146.42M | -135.75M | 74.48M |
| EPS Basic | -0.44 | -1.01 | -1.49 | -1.43 | 1.12 |
| Normalized Basic EPS | -0.27 | -0.62 | -0.92 | -0.89 | 0.70 |
| EPS Diluted | -0.44 | -1.01 | -1.49 | -1.43 | 1.09 |
| Normalized Diluted EPS | -0.27 | -0.62 | -0.92 | -0.89 | 0.69 |
| Average Basic Shares Outstanding | 85.46M | 85.23M | 84.92M | 81.79M | 79.69M |
| Average Diluted Shares Outstanding | 85.46M | 85.23M | 84.92M | 81.79M | 81.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
